Analytical goals for the performance characteristics of assays of haemaoglobin A,, (HbA,,) have been investigated using different assumptions for generation of estimates, these being based on strategies using data on biological variation and on the clinical use of results. The derived goals are highly dependent on the assumptions made. In general, in monitoring of patients (using results from the same laboratory), the analytical imprecision is the most demanding, whereas bias (inaccuracy) is the most important characteristic when strategies for several centres (laboratories) to achieve similar results are invoked. Goals for analytical quality should be given in a form in which both analytical imprecision and bias (or systematic error) are specified. When several goals are to be considered (for different relevant assumptions), the most demanding should be used.
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Assay of glycated haemoglobin, HbA, is now accepted widely as a good index of the mean blood glucose concentration over the preceding 6-8 weeks.' If the test is to be used to advantage, long-term methodological stability is essential, but, in the past, problems with poor assay performance have created some scepticism about its clinical utility. Collaborative studies have shown varying bias and assay imprecision (cV) of 5 to 10% in routine clinical setting^.^^^ In 1984, the National Diabetes Data Group Expert Committee on Glucosylated Hemoglobin (USA) suggested that intra-and inter-assay CVvalues of 5% were attainable, and should be achieved in all l a b o r a t o r i e~.~ These goals for analytical quality are empirical, however, and relate to neither biological variability nor to objective analysis of clinical utility.
Theoretical goals for analytical quality have been postulated based on reference interval^,^-'^ clinicians' opinions,6-11-12 and generalI3-l7 and specific'8-22 evaluations of clinical situations. However, only those based on within-subject biological ~a r i a t i o n '~.~~-~' and on specific Correspondence: Dr Mogens Lytken Larsen.
evaluation of the influence of analytical quality on the utility in monitoring of diabetics28 seem to be relevant for defining goals for the analytical performance of HbA,, assays. Several questions on analytical goals remain unanswered and further investigations are required. In consequence, the aim of the present study was to evaluate strategies for defining analytical goals for HbA,, assays and to estimate additional reliable goals in relation to their clinical use.
MATERIALS AND METHODS

Assay procedure
Measurements of blood haemoglobin A,, (B-HbA,,) were performed by isoelectric focusing2y-w (the units of measurement are percentage HbA,, of total haemoglobin in erythrocytes, and here are termed Vo HbA,,). This method has the highest specificity for HbA,,, and is not subject to interference from other glycated haemoglobins.2 There is no international standard or reference preparation, so the methodological inaccuracy cannot be evaluated; therefore, this must be inferred from the reference interval found in n o n -d i a b e t i~s .~,~ The reference interval has been estimated to be 5.2-6.8% HbA,, using the IFCC-recommended statistical treatment of reference values. The performance characteristics of the method are: within-run imprecision (CVw) = 2.6% and between-run imprecision (CVb) = 1 .O% at a concentration of 10% HbA,,. Using the mean value of duplicate assays, the CV is ,2.62/2+ 1 . 0 2 = 2 . 1%.2y. 31 Analytical bias refers to the deviation of the set-point of the method from the assumed true value, whereas analytical systematic error refers to a sudden, but persistent, deviation from the method's accepted running set-point.
Statistical methods
Within-subject biological variance, s2w.s, was estimated from the statistical model for repeated balanced subsampling (nested d e~i g n ) ,~~.~~ in which the variance for within-subject and analytical variation are separated. Variance homogeneity is illustrated in relation to the X 2distribution as cumulated percentage frequency on a probit scale of standard deviations and , X 2 / D F , where DF is degrees of freedom, four in this study (five samples).
Subjects and specimens
Thirty patients with insulin-dependent diabetes mellitus were regarded in steady state metabolic control after being followed in the out-patient clinic for more than 12 months with regular measurements of HbA,,. Despite attempts to optimize treatment in all patients their HbA,, concentrations had reached three different but very stable levels and the patients were divided into three groups (10 in each) with values around 8% HbA,,, 10% HbA,, and 12% HbA,,, reflecting good, fair and poor metabolic control, respectively. During the following 5 months measurements of HbA,, were performed with 4-6 weeks intervals (five samples). During this period no definitive changes in insulin treatment took place. None of the patients were admitted to hospital because of hypo-or hyperglycaemia and no episodes of intercurrent disease or fever appeared during the study.
GENERATION OF ANALYTICAL GOALS
The generation of analytical goals is based on the following strategies and assumptions.
where CV,_, is the within-subject biological coefficient of ariat ti on,'^-^^-'' but also including systematic error.
Assumption B:
a. an increase in Vo HbA,, of 1 .O will cause 'attention', i.e. a warning to the clinician or some minor change carried out by the patient according to the prevailing circumstances; or b. an increase in Vo HbA,, of 2.0 will cause 'intervention', i.e. a major change of diet and/or insulin therapy.28-32
Assumption C:
The ideal goal for good metabolic control in patients with diabetes mellitus is that the concentration in Yo HbA,, should be below the mean+4*sR (standard deviation of the reference interval of non-diabetics); this corresponds to a Vo HbA,, below 7-5.33-35
MODELS AND RESULTS
Goals based on within-subject biological variation (Assumption A)
The mean values and ranges of HbA,, in the three groups of diabetics (good, fair and poor metabolic control) were 7 -9 (7-5-8.5), 9.9 (9.4-10.6), and 12.4 (11.4-13.4) Vo HbA,,, respectively. The estimated within-subject variations (sW-J in the three groups were: good= 0.70, fair=0.41 and poor=O.65% HbA,,.
The within-subject variation for the group in fair metabolic regulation have the variance homogeneity shown in Fig. 1 with sw-s being 0.41% HbA,,, corresponding to CVW_,=4. 1%. The estimation of goals for analytical quality of HbA,, assays was based on this since the smallest sW+ will give rise to the most stringent analytical goals. The alternative approach of using the simple mathematical average of all published CVw_, has been discussed previ~usly'~ and a goal of CV,=3-3% advocated using the strategy of Harris.15 These goals are closely related t o the situation of estimating a critical difference between two serial measurements in an individual. For P=O-O5, the formula for the least significant difference is: 2.77*CVw_,.
The basic principle is that the analytical variation should not contribute to the overall The estimated goal for imprecision in the HbA,, assays is thus: CV,< %*4-1 = 2.05 (2.1)Vo.
Since the goal for SE ideally is zero, the maximum acceptable combined imprecision and SE (where SE is an analytical systematic change which can occur between two measurements) can be evaluated from A , = 2.77*kVA2 + CV,_,' + SE This describes the maximum acceptable combined imprecision and SE,9-10-37 which is displayed in curve A of Fig. 2 . For negligible imprecision, SE becomes 0-33*CVw-,.
Goals based on clinical significance of a certain change (Assumptions Ba and Bb)
Ba
These goals are based on a situation comparable to Assumption A, but the change, A is a fixed predetermined critical decision-making value. The relationships are described by the formula: Ba: for A 2 = 1.0% HbA,,. and K = 1.28 and Bb: for A2=2.0% HbA,, and K=2.58. Units are % HbA,, or fraction of within-subject variation. Percentage values (at a concentration of 10% HbA,,) are also indicated.
-
,
where K is the appropriate standard deviate from the Gaussian d i s t r i b~t i o n .~~ On rearrangement the maximum CV, becomes:
CV,
A :/(2K2) -CV,.;
Since it has been stated that an increase in To HbA,, of 1 -0 will cause 'attention' (assumption Ba), this change (at 10% HbAJ corresponds to 1 0 ' 7 0 .~~ We suggest that the term 'attention' might be explained in statistical terms as 80% confidence.
This 80% confidence can be expressed in terms of the standard deviate K = 1.28 and goal becomes:
CV, Q 4 1 @/2* 1 .2g2) -4 . I = 3.7% or 0.89*CVW-,. As for model A (above), the maximum acceptable combined imprecision and SE (where SE is an analytical systematic change which has arisen between the two measurements) can be evaluated from -A = K*,2',CVA' + CV-.,'+ SE which is shown in Ba of Fig. 2. or 0.63*CV,.,.
For negligible imprecision, SE becomes 2.6%
Bb Since it has been stated also that an increase in V o Hb,, of 2 -0 will cause 'intervention' (assumption Bb),'" this change at 10% HbA,, corresponds to 20%. Furthermore the term 'intervention' is much more demanding and may be said to correspond to 99% statistical confidence, which in terms of standard deviate corresponds to K = 2-58. Thus, CV, <,2@/(2*2.58') -4 . I ' = 3.6%, which is almost the same analytical goal for imprecision as for 'attention'. Here also the maximum acceptable combined imprecision and SE (where SE is an analytical systematic change which might arise between the two measurements) can be evaluated as illustrated in curve Bb of Fig. 2 .
For negligible imprecision, SE becomes 5 . I% or 1*23*CV,.,.
The three curves shown in Fig. 2 have different shapes, without fixed proportions between analytical bias and imprecision.
The clinical responses detailed above are strictly related to changes of 1.0 and 2.0% HbA,,. Some clinicians will be more and some less demanding. Moreover, even the reactions of the same clinicians might vary from patient to patient. In addition, clinicians might use trends in more than two serial results before taking clinical action. These problems have been discussed previously,'" and will not be repeated here. The conclusion was that the optimal CV, is 2.0% (0-51*CV,.,) and the maximum that is acceptable is 5.0% (1.22*CV,.,) .
Goals based on the criterion that concentrations
should be below 7.5% HbA,, (Assumption C ) One criterion for good metabolic regulation is that the percentage HbA,, should be below 7.5,13-'' and the evaluation of this clinical situation should include goals for both maximum method bias and analytical imprecision. Here the evaluation of goals based on values in Vo HbA,, are more relevant, and s,-, is assumed to be equal to 0.41% HbA,,. Fig. 3 The strategy is to accept an increase in percentage of mearured values above 7.5% HbA,, from loo/, to 20% when the patients biological set point is 7.0% HbA,,. fDotted curves are the curves from Fig. 2.) If it is assumed that there is a 'true' biological homeostatic setpoint of 7.0% HbA,, in a patient, this implies that here will be a distribution of 'true' values around this setpoint with s,-, = 0.41% HbA,,. Half of the values will be above 7.0% HbA,, and half below. Furthermore, 10% of the values will be 2 7 . 5 (from: 7 . 5 -7 . 0 =  1.28*s,_,) . To be 90% sure that a patient's biological setpoint concentration below 7 . 5 is obtained, then assay results should be 7.0% HbA,, or below as shown in Fig. 3(a) .
Analytical imprecision will increase the dispersion of the distribution according to s, , . , _: =sA2 + s, _: .
The maximum acceptable imprecision might be evaluated from the allowable limit that the 90% confidence might decrease to 80%. If this is accepted as reasonable, then the distance from 7 . 5 to 7 . 0 is equal to 0-84*s,,-,-,, and in consequence s,=O.43% HbA,, or 1 . O~* S , _~, as shown in Fig. 3 
(b).
A bias (or persistent SE or a combination) will shift the whole distribution as exemplified in Fig. 3(c) , for bias = 0.16% HbA,,, which equals the situation where 80% of values from a patient with the 'true' biological set point of 7.0 will be measured below 7.5010 HbA,, (with imprecision = 0 and bias = 0 -16% HbA,,).
The maximum acceptable combined imprecision and bias (including persistent SE) can be evaluated as shown in curve C of Fig. 4 . In the figure, the data from Fig. 2 are indicated as dotted curves to illustrate the different courses for combined maximum allowable bias (or SE) and imprecision allowable by use of the different assumptions discussed here.
DISCUSSION
Goals for analytical quality have been postulated using many different strategies, including those, based on biological variation data,5-10-15.23-27 clinical points of view,6-".12 and many other criteria. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Discussion has often been centred on whether one or another analytical goal is the most correct, or on which strategy is most appropriate. All goals, however, are based on some assumptions and are arbitrary in the sense of the degree of variation the analytical performance (and error) may introduce to variability of the true result.37
A real problem may be that when goals are based on certain specific assumptions, they are then generalized to all situations. This may be due to clinical chemists' desires for simple general analytical g o a l~.~~-~I Since monitoring of HbA,, concentration is usually performed in a single hospital, using one analytical method, the problem of bias is somewhat irrelevant when not related to a fixed concentration. The problem of a systematic analytical change YE)'^-^' when monitoring patients over a period of time is however, a realistic possibility, and goals for SE should be included in the goals for imprecision.
It is very interesting to see that the maximum allowable combined SE and imprecision (Assumptions Ba and Bb) have different shapes of curves (Fig. 2) when different assumptions are made.
For goals based on the criterion that ideal concentrations of HbA,, are below 7 . 5 % HbA,, (Assumption C),33-35 a general strategy for several clinics and consequently, several laboratories is introduced. This strategy makes the problem of bias the more important and, at the same time, the goal for imprecision becomes less stringent. It may be difficult to understand what 'values' below 7.5% HbA,, really means or implies, since the within-subject variation is not taken into acount in the original stated c~n c e p t .~~-~~ Our interpretation of the strategy may therefore be different from that really intended by the clinicians. Even when dealing with the perhaps more realistic clinical goals of HbA,, which imply that patients should belong to 'the under 9% club' introduced by Goldstein et al.,32-42 the same analytical goals would be required.
We have only touched upon other important aspects of quality such as analytical specificity. Here, it is important that other haemoglobin forms and derivates are not assayed in the procedure. Goals for this particular quality are difficult to define. In this investigation we have used an analytical method known to show only negligible non-specific reactions.2y Imprecision has been the major consideration in most studies on analytical goals but the present investigation of the nature of goals based on different assumptions has revealed that there is no simple way of including bias which is systematic in type into the imprecision concept. Harris' has sunnested a combination of bias and __ imprecision in a simple model for total error (total error = .imprecision2 + bias2). This may describe the actual situation in an external-control survey, but, according to Gowans et al.y this approach underestimates the effects of bias, leading to a less stringent goal for bias in goal-setting.
In the present investigation, we have dealt with different approaches to analytical goal-setting and we have found that different strategies a n d assumptions will lead to different goals. However, they are probably the best estimates of goals in the situations as we have defined them, but none can be said t o be the most correct. All are, however, more stringent than the 5% for interas well as intra-assay variation recommended by the National Diabetes Data G r o u p Expert Committee on Glucosylated H e m~g l o b i n .~ Optimal analytical performance is a prerequisite for the delivery of useful results t o the clinician, but other elements of 'good laboratory practice' ,43 such as avoiding gross errors (blunders), are also essential.
CONCLUDING REMARKS
A number of different goals for analytical quality can be derived when different assumptions are made When the clinical situation is well defined, the use made of the result should be the basis for goal-setting; if this is unknown, d a t a on biological variation should be the basis for the goal In monitoring of patients-using results from the same laboratory-the analytical imprecision is the most important of the performance characteristics When general strategies-for several centres (laboratories)-are required, the bias is a crucial characteristic If several goals are considered t o be applicable, the most demanding should be used Goals for analytical quality should be given in a form in which both imprecision and bias are defined separately or in combination; other factors such as working range, non-specificity a n d turnaround time should be specified whenever possible, as should important preanalytical factors
